menu
    • menu
    [{"orgOrder":0,"company":"Future Fields","sponsor":"Jenthera Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Future Fields","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Future Fields \/ Jenthera Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Future Fields \/ Jenthera Therapeutics"},{"orgOrder":0,"company":"Infinimmune","sponsor":"Grid Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Infinimmune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Infinimmune \/ Grid Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Infinimmune \/ Grid Therapeutics"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Enara Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Enara Bio \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Enara Bio \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Touchlight","sponsor":"University of Liverpool","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Touchlight","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Touchlight \/ University of Liverpool","highestDevelopmentStatusID":"3","companyTruncated":"Touchlight \/ University of Liverpool"},{"orgOrder":0,"company":"Montai Therapeutics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Montai Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Montai Therapeutics \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Montai Therapeutics \/ Flagship Pioneering"},{"orgOrder":0,"company":"Proxygen","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Proxygen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Proxygen \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Proxygen \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Pure MHC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"ImmunoScape \/ Pure MHC","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScape \/ Pure MHC"},{"orgOrder":0,"company":"Enara Bio","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Enara Bio","amount2":1.0600000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.0600000000000001,"dosageForm":"Injection","sponsorNew":"Enara Bio \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Enara Bio \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Epitopea","sponsor":"Universite de Montreal","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Epitopea","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Epitopea \/ Universite de Montreal","highestDevelopmentStatusID":"3","companyTruncated":"Epitopea \/ Universite de Montreal"},{"orgOrder":0,"company":"Hemogenyx Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hemogenyx Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Hemogenyx Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Hemogenyx Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Theolytics","sponsor":"Epidarex Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Infusion","sponsorNew":"Theolytics \/ Epidarex Capital","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics \/ Epidarex Capital"},{"orgOrder":0,"company":"Theolytics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Theolytics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Theolytics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Theolytics \/ M Ventures"},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0.35999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.35999999999999999,"dosageForm":"Undisclosed","sponsorNew":"BigHat Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"QUANTRO Therapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"QUANTRO Therapeutics","amount2":0.54000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.54000000000000004,"dosageForm":"Undisclosed","sponsorNew":"QUANTRO Therapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"QUANTRO Therapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"AbCellera","sponsor":"Everest Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Everest Medicines","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Everest Medicines"},{"orgOrder":0,"company":"AbCellera","sponsor":"IGM Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ IGM Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ IGM Biosciences"},{"orgOrder":0,"company":"AbCellera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"Invetx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Invetx","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Invetx"},{"orgOrder":0,"company":"AbCellera","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Versant Ventures"},{"orgOrder":0,"company":"Congruence","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Congruence","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Congruence \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Congruence \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"WuXi XDC","sponsor":"Multitude Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"WuXi XDC","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi XDC \/ Multitude Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"WuXi XDC \/ Multitude Therapeutics"},{"orgOrder":0,"company":"Commit Biologics","sponsor":"Bioqube Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Commit Biologics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Commit Biologics \/ Bioqube Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Commit Biologics \/ Bioqube Ventures"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"DAAN Bio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenScript ProBio \/ DAAN Bio Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ DAAN Bio Therapeutics"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"QUANTRO Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"AUSTRIA","productType":"Undisclosed","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"QUANTRO Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"QUANTRO Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"QUANTRO Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"AbCellera","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ AbbVie Inc"},{"orgOrder":0,"company":"Congruence","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Congruence","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Congruence \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Congruence \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Epitopea","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genevant Sciences","amount2":0.12,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.12,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Epitopea","highestDevelopmentStatusID":"3","companyTruncated":"Genevant Sciences \/ Epitopea"},{"orgOrder":0,"company":"WuXi XDC","sponsor":"Ligachem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"WuXi XDC","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"WuXi XDC \/ Ligachem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"WuXi XDC \/ Ligachem Biosciences"},{"orgOrder":0,"company":"Commit Biologics","sponsor":"Korys Investments","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Commit Biologics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Commit Biologics \/ Korys Investments","highestDevelopmentStatusID":"3","companyTruncated":"Commit Biologics \/ Korys Investments"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"Invenra","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ Invenra","highestDevelopmentStatusID":"3","companyTruncated":"Orion Corporation \/ Invenra"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"ProEn Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Biopharmaceuticals \/ ProEn Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"SK Biopharmaceuticals \/ ProEn Therapeutics"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"AbTis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenScript ProBio \/ AbTis","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ AbTis"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Aethon Therapeutics","sponsor":"Revolution Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Aethon Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Aethon Therapeutics \/ Revolution Medicines","highestDevelopmentStatusID":"3","companyTruncated":"Aethon Therapeutics \/ Revolution Medicines"},{"orgOrder":0,"company":"BigHat Biosciences","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BigHat Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BigHat Biosciences \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"BigHat Biosciences \/ Eli Lilly"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Ildong Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Ildong Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Ildong Pharmaceutical"},{"orgOrder":0,"company":"EdiGene","sponsor":"Peking University Cancer Hospital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EdiGene \/ Peking University Cancer Hospital","highestDevelopmentStatusID":"3","companyTruncated":"EdiGene \/ Peking University Cancer Hospital"},{"orgOrder":0,"company":"Proteros","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Proteros","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Proteros \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Proteros \/ AstraZeneca"},{"orgOrder":0,"company":"Sirion Biotech","sponsor":"Cellectis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sirion Biotech","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sirion Biotech \/ Cellectis","highestDevelopmentStatusID":"3","companyTruncated":"Sirion Biotech \/ Cellectis"},{"orgOrder":0,"company":"Glycotope","sponsor":"Byondis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ Byondis","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ Byondis"},{"orgOrder":0,"company":"3T Biosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"3T Biosciences","amount2":0.54000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.54000000000000004,"dosageForm":"Undisclosed","sponsorNew":"3T Biosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"3T Biosciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Aarvik Therapeutics","sponsor":"Arrivent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Aarvik Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Aarvik Therapeutics \/ Arrivent","highestDevelopmentStatusID":"3","companyTruncated":"Aarvik Therapeutics \/ Arrivent"},{"orgOrder":0,"company":"AlivaMab","sponsor":"Teva Pharmaceutical Industries","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AlivaMab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AlivaMab \/ Teva Pharmaceutical Industries","highestDevelopmentStatusID":"3","companyTruncated":"AlivaMab \/ Teva Pharmaceutical Industries"},{"orgOrder":0,"company":"Atomwise","sponsor":"FutuRx","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atomwise","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atomwise \/ FutuRx","highestDevelopmentStatusID":"3","companyTruncated":"Atomwise \/ FutuRx"},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Blacksmith Medicines","amount2":0.29999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.29999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Blacksmith Medicines \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Blacksmith Medicines \/ Eli Lilly"},{"orgOrder":0,"company":"Blacksmith Medicines","sponsor":"Forge Therapeutics, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Merger","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Blacksmith Medicines","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Blacksmith Medicines \/ Forge Therapeutics, Inc","highestDevelopmentStatusID":"3","companyTruncated":"Blacksmith Medicines \/ Forge Therapeutics, Inc"},{"orgOrder":0,"company":"Bolt Biotherapeutics","sponsor":"Genmab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bolt Biotherapeutics","amount2":0.88,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.88,"dosageForm":"Undisclosed","sponsorNew":"Bolt Biotherapeutics \/ Genmab","highestDevelopmentStatusID":"3","companyTruncated":"Bolt Biotherapeutics \/ Genmab"},{"orgOrder":0,"company":"Caribou Biosciences","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caribou Biosciences","amount2":0.34000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.34000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Caribou Biosciences \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Caribou Biosciences \/ AbbVie Inc"},{"orgOrder":0,"company":"Crown Bioscience","sponsor":"ERS Genomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Crown Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Crown Bioscience \/ ERS Genomics","highestDevelopmentStatusID":"3","companyTruncated":"Crown Bioscience \/ ERS Genomics"},{"orgOrder":0,"company":"Degron Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Degron Therapeutics","amount2":1.2,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.2,"dosageForm":"Undisclosed","sponsorNew":"Degron Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Degron Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"EpiBiologics","sponsor":"Digitalis Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EpiBiologics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"EpiBiologics \/ Digitalis Ventures","highestDevelopmentStatusID":"3","companyTruncated":"EpiBiologics \/ Digitalis Ventures"},{"orgOrder":0,"company":"EpiBiologics","sponsor":"Mubadala Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EpiBiologics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"EpiBiologics \/ Mubadala Capital","highestDevelopmentStatusID":"3","companyTruncated":"EpiBiologics \/ Mubadala Capital"},{"orgOrder":0,"company":"GigaMune","sponsor":"Champions Oncology","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GigaMune","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GigaMune \/ Champions Oncology","highestDevelopmentStatusID":"3","companyTruncated":"GigaMune \/ Champions Oncology"},{"orgOrder":0,"company":"Hexagon Bio","sponsor":"Nextech Invest","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hexagon Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Hexagon Bio \/ Nextech Invest","highestDevelopmentStatusID":"3","companyTruncated":"Hexagon Bio \/ Nextech Invest"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":6.1500000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":6.1500000000000004,"dosageForm":"Undisclosed","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"IGM Biosciences","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"IGM Biosciences","amount2":6.1500000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":6.1500000000000004,"dosageForm":"Undisclosed","sponsorNew":"IGM Biosciences \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"IGM Biosciences \/ Sanofi"},{"orgOrder":0,"company":"Kimia Therapeutics","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kimia Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Kimia Therapeutics \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Kimia Therapeutics \/ The Column Group"},{"orgOrder":0,"company":"La Jolla Institute","sponsor":"Cytocom","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"La Jolla Institute","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"La Jolla Institute \/ Cytocom","highestDevelopmentStatusID":"3","companyTruncated":"La Jolla Institute \/ Cytocom"},{"orgOrder":0,"company":"Plexium","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0.5,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.5,"dosageForm":"Undisclosed","sponsorNew":"Plexium \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ Amgen Inc"},{"orgOrder":0,"company":"Poseida Therapeutics, Inc","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Poseida Therapeutics, Inc","amount2":0.59999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.59999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Poseida Therapeutics, Inc \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Poseida Therapeutics, Inc \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Radionetics Oncology","amount2":1,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Radionetics Oncology \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Radionetics Oncology \/ Eli Lilly"},{"orgOrder":0,"company":"RenovoRx","sponsor":"Imugene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"RenovoRx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RenovoRx \/ Imugene","highestDevelopmentStatusID":"3","companyTruncated":"RenovoRx \/ Imugene"},{"orgOrder":0,"company":"Rondo Therapeutics","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Rondo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Rondo Therapeutics \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Rondo Therapeutics \/ Eli Lilly"},{"orgOrder":0,"company":"Scribe Therapeutics","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scribe Therapeutics","amount2":1.03,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Undisclosed","sponsorNew":"Scribe Therapeutics \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Scribe Therapeutics \/ Sanofi"},{"orgOrder":0,"company":"Shoreline Biosciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Shoreline Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shoreline Biosciences \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Shoreline Biosciences \/ Inapplicable"},{"orgOrder":0,"company":"Sinopia Biosciences","sponsor":"National Institute of General Medical Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Sinopia Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sinopia Biosciences \/ National Institute of General Medical Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Sinopia Biosciences \/ National Institute of General Medical Sciences"},{"orgOrder":0,"company":"SyntheX","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SyntheX","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"Undisclosed","sponsorNew":"SyntheX \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"SyntheX \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Tentarix Biotherapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Tentarix Biotherapeutics \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"TumorGen","sponsor":"The Division of Cancer Treatment and Diagnosis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TumorGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"TumorGen \/ The Division of Cancer Treatment and Diagnosis","highestDevelopmentStatusID":"3","companyTruncated":"TumorGen \/ The Division of Cancer Treatment and Diagnosis"},{"orgOrder":0,"company":"TwoStep Therapeutics","sponsor":"NFX Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TwoStep Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"TwoStep Therapeutics \/ NFX Bio","highestDevelopmentStatusID":"3","companyTruncated":"TwoStep Therapeutics \/ NFX Bio"},{"orgOrder":0,"company":"Valora Therapeutics","sponsor":"Avalon BioVentures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Valora Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Valora Therapeutics \/ Avalon BioVentures","highestDevelopmentStatusID":"3","companyTruncated":"Valora Therapeutics \/ Avalon BioVentures"},{"orgOrder":0,"company":"VeriSIM Life","sponsor":"Mayo Clinic","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"VeriSIM Life","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"VeriSIM Life \/ Mayo Clinic","highestDevelopmentStatusID":"3","companyTruncated":"VeriSIM Life \/ Mayo Clinic"},{"orgOrder":0,"company":"Vicinitas Therapeutics","sponsor":"16z","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vicinitas Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Vicinitas Therapeutics \/ 16z","highestDevelopmentStatusID":"3","companyTruncated":"Vicinitas Therapeutics \/ 16z"},{"orgOrder":0,"company":"Artisan Bio","sponsor":"BrightPath Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artisan Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artisan Bio \/ BrightPath Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Artisan Bio \/ BrightPath Biotherapeutics"},{"orgOrder":0,"company":"Nexo Therapeutics","sponsor":"Versant Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nexo Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Nexo Therapeutics \/ Versant Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nexo Therapeutics \/ Versant Ventures"},{"orgOrder":0,"company":"Artizan Bioscience","sponsor":"University Medical Center Utrecht","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artizan Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Artizan Bioscience \/ University Medical Center Utrecht","highestDevelopmentStatusID":"3","companyTruncated":"Artizan Bioscience \/ University Medical Center Utrecht"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"University of Oxford","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EvolveImmune Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ University of Oxford","highestDevelopmentStatusID":"3","companyTruncated":"EvolveImmune Therapeutics \/ University of Oxford"},{"orgOrder":0,"company":"Terremoto Biosciences","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Terremoto Biosciences","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Terremoto Biosciences \/ OrbiMed Advisors","highestDevelopmentStatusID":"3","companyTruncated":"Terremoto Biosciences \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0.16,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"4SR Biosciences","sponsor":"hC Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"4SR Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"4SR Biosciences \/ hC Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"4SR Biosciences \/ hC Bioscience"},{"orgOrder":0,"company":"Confo Therapeutics","sponsor":"Regeneron Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"BELGIUM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Confo Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Confo Therapeutics \/ Regeneron Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Confo Therapeutics \/ Regeneron Pharmaceuticals"},{"orgOrder":0,"company":"48Hour Discovery","sponsor":"Alberta Cancer Foundation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"48Hour Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"48Hour Discovery \/ Alberta Cancer Foundation","highestDevelopmentStatusID":"3","companyTruncated":"48Hour Discovery \/ Alberta Cancer Foundation"},{"orgOrder":0,"company":"48Hour Discovery","sponsor":"Oranomed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"48Hour Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"48Hour Discovery \/ Oranomed","highestDevelopmentStatusID":"3","companyTruncated":"48Hour Discovery \/ Oranomed"},{"orgOrder":0,"company":"Ability Biologics","sponsor":"Charles River Laboratories, Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ability Biologics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Ability Biologics \/ Charles River Laboratories, Inc","highestDevelopmentStatusID":"3","companyTruncated":"Ability Biologics \/ Charles River Laboratories, Inc"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"Pepscan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ Pepscan","highestDevelopmentStatusID":"3","companyTruncated":"Fusion Pharma \/ Pepscan"},{"orgOrder":0,"company":"ME Therapeutics","sponsor":"NanoVation Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ME Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ME Therapeutics \/ NanoVation Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"ME Therapeutics \/ NanoVation Therapeutics"},{"orgOrder":0,"company":"Orion Biotechnology","sponsor":"Peptilogics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Orion Biotechnology","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Biotechnology \/ Peptilogics","highestDevelopmentStatusID":"3","companyTruncated":"Orion Biotechnology \/ Peptilogics"},{"orgOrder":0,"company":"Alternative Bio","sponsor":"F-Prime Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alternative Bio","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Alternative Bio \/ F-Prime Capital","highestDevelopmentStatusID":"3","companyTruncated":"Alternative Bio \/ F-Prime Capital"},{"orgOrder":0,"company":"EdiGene","sponsor":"Neukio BioTherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EdiGene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"EdiGene \/ Neukio BioTherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"EdiGene \/ Neukio BioTherapeutics"},{"orgOrder":0,"company":"Escugen","sponsor":"InxMed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Escugen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Escugen \/ InxMed","highestDevelopmentStatusID":"3","companyTruncated":"Escugen \/ InxMed"},{"orgOrder":0,"company":"HitGen","sponsor":"Bridge Biotherapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Bridge Biotherapeutics","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Bridge Biotherapeutics"},{"orgOrder":0,"company":"HitGen","sponsor":"Uppthera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Uppthera","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Uppthera"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Exscientia","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huadong Medicine \/ Exscientia","highestDevelopmentStatusID":"3","companyTruncated":"Huadong Medicine \/ Exscientia"},{"orgOrder":0,"company":"neoX Biotech","sponsor":"Sky9 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"neoX Biotech","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"neoX Biotech \/ Sky9 Capital","highestDevelopmentStatusID":"3","companyTruncated":"neoX Biotech \/ Sky9 Capital"},{"orgOrder":0,"company":"Vipergen","sponsor":"PhoreMost","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vipergen \/ PhoreMost","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/ PhoreMost"},{"orgOrder":0,"company":"Vipergen","sponsor":"Theseus Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"DENMARK","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vipergen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vipergen \/ Theseus Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Vipergen \/ Theseus Pharmaceuticals"},{"orgOrder":0,"company":"Glykos","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glykos","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glykos \/ Orion Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Glykos \/ Orion Corporation"},{"orgOrder":0,"company":"Argobio","sponsor":"Oncode Bridge Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Argobio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Argobio \/ Oncode Bridge Fund","highestDevelopmentStatusID":"3","companyTruncated":"Argobio \/ Oncode Bridge Fund"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":1.48,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.48,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Mablink Bioscience","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Mablink Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Mablink Bioscience \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Mablink Bioscience \/ Eli Lilly"},{"orgOrder":0,"company":"Mnemo Therapeutics","sponsor":"Casdin Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Mnemo Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Mnemo Therapeutics \/ Casdin Capital","highestDevelopmentStatusID":"3","companyTruncated":"Mnemo Therapeutics \/ Casdin Capital"},{"orgOrder":0,"company":"Synsight","sponsor":"Iktos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2024","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Synsight","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Synsight \/ Iktos","highestDevelopmentStatusID":"3","companyTruncated":"Synsight \/ Iktos"},{"orgOrder":0,"company":"Transgene","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Termination","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Transgene","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Transgene \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Transgene \/ AstraZeneca"},{"orgOrder":0,"company":"Syracuse Biopharma","sponsor":"JW Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Syracuse Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Syracuse Biopharma \/ JW Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Syracuse Biopharma \/ JW Therapeutics"},{"orgOrder":0,"company":"Turbine","sponsor":"Harmonic Discovery","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turbine \/ Harmonic Discovery","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ Harmonic Discovery"},{"orgOrder":0,"company":"Turbine","sponsor":"MSD Global Health Innovation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Turbine \/ MSD Global Health Innovation","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ MSD Global Health Innovation"},{"orgOrder":0,"company":"Turbine","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turbine \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Turbine","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turbine \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoreason \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Cytoreason \/ Merck & Co"},{"orgOrder":0,"company":"PeptiDream","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2024","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":2.8900000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":2.8900000000000001,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Anavo Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Anavo Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Anavo Therapeutics \/ M Ventures"},{"orgOrder":0,"company":"CureVac","sponsor":"CureVac","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"CureVac","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"CureVac \/ CureVac","highestDevelopmentStatusID":"3","companyTruncated":"CureVac \/ CureVac"},{"orgOrder":0,"company":"ARTBIO","sponsor":"Parabilis Medicines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ARTBIO","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ARTBIO \/ FogPharma","highestDevelopmentStatusID":"3","companyTruncated":"ARTBIO \/ FogPharma"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"nCage Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ryvu Therapeutics \/ nCage Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Ryvu Therapeutics \/ nCage Therapeutics"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Anzu Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"ImmunoScape \/ Anzu Partners","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScape \/ Anzu Partners"},{"orgOrder":0,"company":"Bridge Biotherapeutics","sponsor":"Scripps Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bridge Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bridge Biotherapeutics \/ Scripps Research","highestDevelopmentStatusID":"3","companyTruncated":"Bridge Biotherapeutics \/ Scripps Research"},{"orgOrder":0,"company":"Genome & Company","sponsor":"Debiopharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genome & Company","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genome & Company \/ Debiopharm","highestDevelopmentStatusID":"3","companyTruncated":"Genome & Company \/ Debiopharm"},{"orgOrder":0,"company":"Shaperon","sponsor":"Dong-A ST Co., Ltd.","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Shaperon","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Shaperon \/ Dong-A ST Co., Ltd.","highestDevelopmentStatusID":"3","companyTruncated":"Shaperon \/ Dong-A ST Co., Ltd."},{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Y-Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Y-Biologics \/ Pierre Fabre"},{"orgOrder":0,"company":"BioInvent","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"BioInvent \/ Exelixis"},{"orgOrder":0,"company":"Numab Therapeutics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Numab Therapeutics","amount2":0.28000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.28000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Numab Therapeutics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Numab Therapeutics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"T3 Pharma","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWITZERLAND","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"T3 Pharma","amount2":0.51000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.51000000000000001,"dosageForm":"Undisclosed","sponsorNew":"T3 Pharma \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"T3 Pharma \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Development Center for Biotechnology","sponsor":"HoneyBear Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Development Center for Biotechnology","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Development Center for Biotechnology \/ HoneyBear Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Development Center for Biotechnology \/ HoneyBear Biosciences"},{"orgOrder":0,"company":"Antiverse","sponsor":"GlobalBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antiverse \/ GlobalBio","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ GlobalBio"},{"orgOrder":0,"company":"Antiverse","sponsor":"i&i Biotech Fund I","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Antiverse","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Antiverse \/ i&i Biotech Fund I","highestDevelopmentStatusID":"3","companyTruncated":"Antiverse \/ i&i Biotech Fund I"},{"orgOrder":0,"company":"Crescendo Biologics Ltd","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Crescendo Biologics Ltd","amount2":0.79000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.79000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Crescendo Biologics Ltd \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"Crescendo Biologics Ltd \/ BioNTech"},{"orgOrder":0,"company":"Curve Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Curve Therapeutics","amount2":1.7,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.7,"dosageForm":"Undisclosed","sponsorNew":"Curve Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Curve Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"LabGenius","sponsor":"Innovate Biopharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LabGenius","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"LabGenius \/ Innovate Biopharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"LabGenius \/ Innovate Biopharmaceuticals"},{"orgOrder":0,"company":"LabGenius","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LabGenius","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"LabGenius \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"LabGenius \/ M Ventures"},{"orgOrder":0,"company":"Macomics","sponsor":"IFOM","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Macomics \/ IFOM","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ IFOM"},{"orgOrder":0,"company":"Outrun Therapeutics","sponsor":"M Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Outrun Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Outrun Therapeutics \/ M Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Outrun Therapeutics \/ M Ventures"},{"orgOrder":0,"company":"T-Therapeutics","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"T-Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"T-Therapeutics \/ Sofinnova Partners","highestDevelopmentStatusID":"3","companyTruncated":"T-Therapeutics \/ Sofinnova Partners"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ubiquigent \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Ubiquigent \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Vernalis","sponsor":"HOX Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vernalis \/ HOX Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Vernalis \/ HOX Therapeutics"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Lion TCR","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ Lion TCR","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ Lion TCR"},{"orgOrder":0,"company":"MaxCyte","sponsor":"Walking Fish Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MaxCyte","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MaxCyte \/ Walking Fish Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"MaxCyte \/ Walking Fish Therapeutics"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Twist Bioscience","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0.19,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Twist Bioscience \/ Twist Bioscience","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Twist Bioscience"},{"orgOrder":0,"company":"Aitia","sponsor":"Orion Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Aitia","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Aitia \/ Orion Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Aitia \/ Orion Corporation"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloy Therapeutics \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Alloy Therapeutics","sponsor":"Tegmine Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alloy Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alloy Therapeutics \/ Tegmine Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Alloy Therapeutics \/ Tegmine Therapeutics"},{"orgOrder":0,"company":"Arrakis Therapeutics","sponsor":"Amgen Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Arrakis Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Arrakis Therapeutics \/ Amgen Inc","highestDevelopmentStatusID":"3","companyTruncated":"Arrakis Therapeutics \/ Amgen Inc"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"Plex Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Atavistik Bio \/ Plex Research","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ Plex Research"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Atavistik Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ The Column Group"},{"orgOrder":0,"company":"Biolojic Design","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biolojic Design","amount2":0.38,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"Biolojic Design \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"Biolojic Design \/ Merck Group"},{"orgOrder":0,"company":"Candel Therapeutics","sponsor":"University of Pennsylvania","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Candel Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Candel Therapeutics \/ University of Pennsylvania","highestDevelopmentStatusID":"3","companyTruncated":"Candel Therapeutics \/ University of Pennsylvania"},{"orgOrder":0,"company":"Charles River Laboratories, Inc","sponsor":"Related Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Charles River Laboratories, Inc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Charles River Laboratories, Inc \/ Related Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Charles River Laboratories, Inc \/ Related Sciences"},{"orgOrder":0,"company":"Delphia Therapeutics","sponsor":"Google Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Delphia Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.070000000000000007,"dosageForm":"Undisclosed","sponsorNew":"Delphia Therapeutics \/ Google Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Delphia Therapeutics \/ Google Ventures"},{"orgOrder":0,"company":"EnPlusOne Biosciences","sponsor":"Wyss Institute","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EnPlusOne Biosciences","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"EnPlusOne Biosciences \/ Wyss Institute","highestDevelopmentStatusID":"3","companyTruncated":"EnPlusOne Biosciences \/ Wyss Institute"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Flare Therapeutics","amount2":1.8700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.8700000000000001,"dosageForm":"Undisclosed","sponsorNew":"Flare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Flare Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Flare Therapeutics","amount2":1.8700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.8700000000000001,"dosageForm":"Undisclosed","sponsorNew":"Flare Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Flare Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Loxo Oncology Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0.38,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.38,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Loxo Oncology Inc","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Therapeutics \/ Loxo Oncology Inc"},{"orgOrder":0,"company":"Genocea","sponsor":"JANSSEN BIOTECH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genocea","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Genocea \/ Janssen Biotech","highestDevelopmentStatusID":"3","companyTruncated":"Genocea \/ Janssen Biotech"},{"orgOrder":0,"company":"Hopewell Therapeutics","sponsor":"Mass Ave Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hopewell Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Hopewell Therapeutics \/ Mass Ave Capital","highestDevelopmentStatusID":"3","companyTruncated":"Hopewell Therapeutics \/ Mass Ave Capital"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Caris Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HotSpot Therapeutics \/ Caris Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Caris Life Sciences"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Pivotal Bioventure Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"HotSpot Therapeutics \/ Pivotal Bioventure Partners","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Pivotal Bioventure Partners"},{"orgOrder":0,"company":"Jura Bio","sponsor":"Replay Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Jura Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Jura Bio \/ Replay Bio","highestDevelopmentStatusID":"3","companyTruncated":"Jura Bio \/ Replay Bio"},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kelonia Therapeutics","amount2":0.83999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.83999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Kelonia Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Kelonia Therapeutics \/ Xyphos Biosciences"},{"orgOrder":0,"company":"Kojin Therapeutics","sponsor":"Polaris Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kojin Therapeutics","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Kojin Therapeutics \/ Polaris Partners","highestDevelopmentStatusID":"3","companyTruncated":"Kojin Therapeutics \/ Polaris Partners"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Fidelity Management & Research Company","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series C Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0.17999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"LifeMine Therapeutics \/ Fidelity Management & Research Company","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine Therapeutics \/ Fidelity Management & Research Company"},{"orgOrder":0,"company":"MOMA Therapeutics","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MOMA Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"MOMA Therapeutics \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"MOMA Therapeutics \/ Bayer AG"},{"orgOrder":0,"company":"MOMA Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"MOMA Therapeutics","amount2":2.0699999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":2.0699999999999998,"dosageForm":"Undisclosed","sponsorNew":"MOMA Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"MOMA Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"NextRNA","sponsor":"Cobro Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"NextRNA","amount2":0.059999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.059999999999999998,"dosageForm":"Undisclosed","sponsorNew":"NextRNA \/ Cobro Ventures","highestDevelopmentStatusID":"3","companyTruncated":"NextRNA \/ Cobro Ventures"},{"orgOrder":0,"company":"Nirogy therapeutics","sponsor":"Sante Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nirogy therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Nirogy therapeutics \/ Sante Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Nirogy therapeutics \/ Sante Ventures"},{"orgOrder":0,"company":"Omega Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Omega Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Omega Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Omega Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Passkey Therapeutics","sponsor":"Breakout Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Passkey Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"Passkey Therapeutics \/ Breakout Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Passkey Therapeutics \/ Breakout Ventures"},{"orgOrder":0,"company":"Pearl Bio","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Pearl Bio","amount2":1,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"Pearl Bio \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Pearl Bio \/ Merck & Co"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.04,"dosageForm":"Undisclosed","sponsorNew":"Remix Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":1.05,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.05,"dosageForm":"Undisclosed","sponsorNew":"Remix Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ GSK"},{"orgOrder":0,"company":"Rgenta Therapeutics","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Rgenta Therapeutics","amount2":0.55000000000000004,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.55000000000000004,"dosageForm":"Undisclosed","sponsorNew":"Rgenta Therapeutics \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Rgenta Therapeutics \/ GSK"},{"orgOrder":0,"company":"SaponiQx","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SaponiQx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SaponiQx \/ Ginkgo Bioworks","highestDevelopmentStatusID":"3","companyTruncated":"SaponiQx \/ Ginkgo Bioworks"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scorpion Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Scorpion Therapeutics \/ AstraZeneca"},{"orgOrder":0,"company":"Solu Therapeutics","sponsor":"Longwood Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Solu Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Solu Therapeutics \/ Longwood Fund","highestDevelopmentStatusID":"3","companyTruncated":"Solu Therapeutics \/ Longwood Fund"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"OmniAb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Talem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talem Therapeutics \/ OmniAb","highestDevelopmentStatusID":"3","companyTruncated":"Talem Therapeutics \/ OmniAb"},{"orgOrder":0,"company":"Third Arc Bio","sponsor":"Vida Ventures LLC","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Third Arc Bio","amount2":0.17000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Third Arc Bio \/ Vida Ventures LLC","highestDevelopmentStatusID":"3","companyTruncated":"Third Arc Bio \/ Vida Ventures LLC"},{"orgOrder":0,"company":"TRIANA Biomedicines","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"TRIANA Biomedicines","amount2":1.55,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.55,"dosageForm":"Undisclosed","sponsorNew":"TRIANA Biomedicines \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"TRIANA Biomedicines \/ Pfizer Inc"},{"orgOrder":0,"company":"Twelve Bio","sponsor":"Ensoma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twelve Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Twelve Bio \/ Ensoma","highestDevelopmentStatusID":"3","companyTruncated":"Twelve Bio \/ Ensoma"},{"orgOrder":0,"company":"XtalPi","sponsor":"CK Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XtalPi \/ CK Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ CK Life Sciences"},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Amphilix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofins Discovery \/ Amphilix","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins Discovery \/ Amphilix"},{"orgOrder":0,"company":"GenScript","sponsor":"Remd","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenScript \/ Remd","highestDevelopmentStatusID":"3","companyTruncated":"GenScript \/ Remd"},{"orgOrder":0,"company":"Bristol Myers Squibb","sponsor":"Ubiquigent","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bristol Myers Squibb","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bristol Myers Squibb \/ Ubiquigent","highestDevelopmentStatusID":"3","companyTruncated":"Bristol Myers Squibb \/ Ubiquigent"},{"orgOrder":0,"company":"OverT Bio","sponsor":"ARTIS Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"OverT Bio","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"OverT Bio \/ ARTIS Ventures","highestDevelopmentStatusID":"3","companyTruncated":"OverT Bio \/ ARTIS Ventures"},{"orgOrder":0,"company":"OverT Bio","sponsor":"ScaleReady","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Funding","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"OverT Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"OverT Bio \/ ScaleReady","highestDevelopmentStatusID":"3","companyTruncated":"OverT Bio \/ ScaleReady"},{"orgOrder":0,"company":"Roivant Sciences","sponsor":"SK Holdings","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Roivant Sciences","amount2":0.20000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.20000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Roivant Sciences \/ SK Holdings","highestDevelopmentStatusID":"3","companyTruncated":"Roivant Sciences \/ SK Holdings"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaccinex \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Vaccinex \/ Undisclosed"},{"orgOrder":0,"company":"Cereius","sponsor":"Solve Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cereius","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cereius \/ Solve Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cereius \/ Solve Therapeutics"},{"orgOrder":0,"company":"Cevec","sponsor":"Carisma Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cevec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cevec \/ Carisma Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Cevec \/ Carisma Therapeutics"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Optimeos Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Optimeos Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Optimeos Life Sciences"},{"orgOrder":0,"company":"BioMed X","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioMed X","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMed X \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"BioMed X \/ Inapplicable"},{"orgOrder":0,"company":"Abexxa Biologics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Abexxa Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Abexxa Biologics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Abexxa Biologics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":1.3999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.3999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Caris Life Sciences \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Merck Group"},{"orgOrder":0,"company":"Molecular Templates","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Molecular Templates","amount2":1.3700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.3700000000000001,"dosageForm":"Undisclosed","sponsorNew":"Molecular Templates \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Molecular Templates \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Recursion Pharma","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Recursion Pharma","amount2":1.5,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"Undisclosed","sponsorNew":"Recursion Pharma \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"Recursion Pharma \/ Bayer AG"},{"orgOrder":0,"company":"Abiologics","sponsor":"Flagship Pioneering","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Abiologics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Abiologics \/ Flagship Pioneering","highestDevelopmentStatusID":"3","companyTruncated":"Abiologics \/ Flagship Pioneering"},{"orgOrder":0,"company":"AbSci","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbSci \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"AbSci \/ AstraZeneca"},{"orgOrder":0,"company":"AbSci","sponsor":"Memorial Sloan Kettering Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbSci","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbSci \/ Memorial Sloan Kettering Cancer Center","highestDevelopmentStatusID":"3","companyTruncated":"AbSci \/ Memorial Sloan Kettering Cancer Center"},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Acquisition","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Bonum Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Bonum Therapeutics","sponsor":"Roche Venture Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Bonum Therapeutics","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Bonum Therapeutics \/ Roche Venture Fund","highestDevelopmentStatusID":"3","companyTruncated":"Bonum Therapeutics \/ Roche Venture Fund"},{"orgOrder":0,"company":"Invenra","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Invenra","amount2":0.48999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.48999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Invenra \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"Invenra \/ Exelixis"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"DISCO Pharmaceuticals","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2024","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"DISCO Pharmaceuticals","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"DISCO Pharmaceuticals \/ Sofinnova Partners","highestDevelopmentStatusID":"3","companyTruncated":"DISCO Pharmaceuticals \/ Sofinnova Partners"},{"orgOrder":0,"company":"Cartography Biosciences","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cartography Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cartography Biosciences \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Cartography Biosciences \/ Gilead Sciences"},{"orgOrder":0,"company":"Elix","sponsor":"Prism Biolab","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Elix","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Elix \/ PRISM BioLab","highestDevelopmentStatusID":"3","companyTruncated":"Elix \/ PRISM BioLab"},{"orgOrder":0,"company":"AbCellera","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Incyte Corporation"},{"orgOrder":0,"company":"AbCellera","sponsor":"OrbiMed Advisors","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ OrbiMed Advisors","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ OrbiMed Advisors"},{"orgOrder":0,"company":"Orion Corporation","sponsor":"CuraTeQ Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FINLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Orion Corporation","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Orion Corporation \/ CuraTeQ Biologics","highestDevelopmentStatusID":"3","companyTruncated":"Orion Corporation \/ CuraTeQ Biologics"},{"orgOrder":0,"company":"SK Biopharmaceuticals","sponsor":"KIRAMS","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SK Biopharmaceuticals","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Biopharmaceuticals \/ KIRAMS","highestDevelopmentStatusID":"3","companyTruncated":"SK Biopharmaceuticals \/ KIRAMS"},{"orgOrder":0,"company":"GenScript ProBio","sponsor":"AskGene Pharma Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GenScript ProBio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GenScript ProBio \/ AskGene Pharma Inc","highestDevelopmentStatusID":"3","companyTruncated":"GenScript ProBio \/ AskGene Pharma Inc"},{"orgOrder":0,"company":"Aethon Therapeutics","sponsor":"Apple Tree Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Aethon Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Aethon Therapeutics \/ Apple Tree Partners","highestDevelopmentStatusID":"3","companyTruncated":"Aethon Therapeutics \/ Apple Tree Partners"},{"orgOrder":0,"company":"Tavros Therapeutics","sponsor":"Vividion Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tavros Therapeutics","amount2":0.45000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.45000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Tavros Therapeutics \/ Vividion Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Tavros Therapeutics \/ Vividion Therapeutics"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Bayer AG","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0.19,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Bayer AG","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Bayer AG"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0.70999999999999996,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.70999999999999996,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Inapplicable"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"J.P. Morgan","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Public Offering","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0.25,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.25,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ J.P. Morgan","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ J.P. Morgan"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MediSix","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ MediSix","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ MediSix"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"MOLCURE Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ MOLCURE Inc","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ MOLCURE Inc"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Neogene","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Neogene","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Neogene"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Seismic Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Seismic Bio","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Seismic Bio"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Takeda Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Takeda Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Takeda Pharmaceutical"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Inhalation","sponsorNew":"Twist Bioscience \/ Astellas Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Astellas Pharma"},{"orgOrder":0,"company":"Glycotope","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ Evotec"},{"orgOrder":0,"company":"Glycotope","sponsor":"LegoChem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Glycotope","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Glycotope \/ LegoChem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Glycotope \/ LegoChem Biosciences"},{"orgOrder":0,"company":"3T Biosciences","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"3T Biosciences","amount2":0.27000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.27000000000000002,"dosageForm":"Undisclosed","sponsorNew":"3T Biosciences \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"3T Biosciences \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Hexagon Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Hexagon Bio","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Hexagon Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Hexagon Bio \/ The Column Group"},{"orgOrder":0,"company":"Plexium","sponsor":"BVF Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Plexium","amount2":0.10000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Plexium \/ BVF Partners","highestDevelopmentStatusID":"3","companyTruncated":"Plexium \/ BVF Partners"},{"orgOrder":0,"company":"Radionetics Oncology","sponsor":"Frazier Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Radionetics Oncology","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Radionetics Oncology \/ Frazier Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Radionetics Oncology \/ Frazier Life Sciences"},{"orgOrder":0,"company":"Tentarix Biotherapeutics","sponsor":"Gilead Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Tentarix Biotherapeutics","amount2":0.31,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.31,"dosageForm":"Undisclosed","sponsorNew":"Tentarix Biotherapeutics \/ Gilead Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Tentarix Biotherapeutics \/ Gilead Sciences"},{"orgOrder":0,"company":"Terremoto Biosciences","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Terremoto Biosciences","amount2":0.17999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.17999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Terremoto Biosciences \/ EcoR1 Capital","highestDevelopmentStatusID":"3","companyTruncated":"Terremoto Biosciences \/ EcoR1 Capital"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":5.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":5.2000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":5.2000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":5.2000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ Bristol Myers Squibb","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ Bristol Myers Squibb"},{"orgOrder":0,"company":"Evotec","sponsor":"GSK","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Evotec","amount2":0.34999999999999998,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.34999999999999998,"dosageForm":"Undisclosed","sponsorNew":"Evotec \/ GSK","highestDevelopmentStatusID":"3","companyTruncated":"Evotec \/ GSK"},{"orgOrder":0,"company":"Fusion Pharma","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Fusion Pharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fusion Pharma \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Fusion Pharma \/ AstraZeneca"},{"orgOrder":0,"company":"HitGen","sponsor":"ARase Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ ARase Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ ARase Therapeutics"},{"orgOrder":0,"company":"HitGen","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Merck & Co"},{"orgOrder":0,"company":"HitGen","sponsor":"Uppthera","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HitGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HitGen \/ Uppthera","highestDevelopmentStatusID":"3","companyTruncated":"HitGen \/ Uppthera"},{"orgOrder":0,"company":"Huadong Medicine","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Huadong Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Huadong Medicine \/ Insilico Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Huadong Medicine \/ Insilico Medicine"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":1.5,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Cytoreason","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cytoreason","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cytoreason \/ Pfizer Inc","highestDevelopmentStatusID":"3","companyTruncated":"Cytoreason \/ Pfizer Inc"},{"orgOrder":0,"company":"PeptiDream","sponsor":"RayzeBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Undisclosed","year":"2022","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"PeptiDream","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"PeptiDream \/ RayzeBio","highestDevelopmentStatusID":"3","companyTruncated":"PeptiDream \/ RayzeBio"},{"orgOrder":0,"company":"Anavo Therapeutics","sponsor":"MRL Ventures Fund","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Anavo Therapeutics","amount2":0.029999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Anavo Therapeutics \/ MRL Ventures Fund","highestDevelopmentStatusID":"3","companyTruncated":"Anavo Therapeutics \/ MRL Ventures Fund"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"BioNTech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ryvu Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ryvu Therapeutics \/ BioNTech","highestDevelopmentStatusID":"3","companyTruncated":"Ryvu Therapeutics \/ BioNTech"},{"orgOrder":0,"company":"Ryvu Therapeutics","sponsor":"Exelixis","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"POLAND","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ryvu Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ryvu Therapeutics \/ Exelixis","highestDevelopmentStatusID":"3","companyTruncated":"Ryvu Therapeutics \/ Exelixis"},{"orgOrder":0,"company":"ImmunoScape","sponsor":"Experimental Drug Development Centre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SINGAPORE","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoScape","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ImmunoScape \/ Experimental Drug Development Centre","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoScape \/ Experimental Drug Development Centre"},{"orgOrder":0,"company":"Macomics","sponsor":"Caribou Property Limited","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Macomics \/ Caribou Property Limited","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ Caribou Property Limited"},{"orgOrder":0,"company":"Macomics","sponsor":"Ono Pharmaceutical","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Macomics \/ Ono Pharmaceutical","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ Ono Pharmaceutical"},{"orgOrder":0,"company":"Ubiquigent","sponsor":"Nanna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ubiquigent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ubiquigent \/ Nanna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Ubiquigent \/ Nanna Therapeutics"},{"orgOrder":0,"company":"Vernalis","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vernalis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vernalis \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Vernalis \/ Pierre Fabre"},{"orgOrder":0,"company":"Twist Bioscience","sponsor":"Nkarta Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Twist Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Twist Bioscience \/ Nkarta Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Twist Bioscience \/ Nkarta Therapeutics"},{"orgOrder":0,"company":"Arrakis Therapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Arrakis Therapeutics","amount2":0.19,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Arrakis Therapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Arrakis Therapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Atavistik Bio","sponsor":"The Column Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Atavistik Bio","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Atavistik Bio \/ The Column Group","highestDevelopmentStatusID":"3","companyTruncated":"Atavistik Bio \/ The Column Group"},{"orgOrder":0,"company":"Flare Therapeutics","sponsor":"Third Rock Ventures","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Flare Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Flare Therapeutics \/ Third Rock Ventures","highestDevelopmentStatusID":"3","companyTruncated":"Flare Therapeutics \/ Third Rock Ventures"},{"orgOrder":0,"company":"Foghorn Therapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Foghorn Therapeutics","amount2":0.42999999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.42999999999999999,"dosageForm":"Undisclosed","sponsorNew":"Foghorn Therapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Foghorn Therapeutics \/ Merck & Co"},{"orgOrder":0,"company":"LifeMine Therapeutics","sponsor":"Rick Klausner","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"LifeMine Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"LifeMine Therapeutics \/ Rick Klausner","highestDevelopmentStatusID":"3","companyTruncated":"LifeMine Therapeutics \/ Rick Klausner"},{"orgOrder":0,"company":"Scorpion Therapeutics","sponsor":"Boxer Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Series B Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Scorpion Therapeutics","amount2":0.16,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.16,"dosageForm":"Undisclosed","sponsorNew":"Scorpion Therapeutics \/ Boxer Capital","highestDevelopmentStatusID":"3","companyTruncated":"Scorpion Therapeutics \/ Boxer Capital"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Talem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talem Therapeutics \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Talem Therapeutics \/ Pierre Fabre"},{"orgOrder":0,"company":"Talem Therapeutics","sponsor":"Xyphos Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Talem Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Talem Therapeutics \/ Xyphos Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"Talem Therapeutics \/ Xyphos Biosciences"},{"orgOrder":0,"company":"XtalPi","sponsor":"Incendia Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"XtalPi","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"XtalPi \/ Incendia Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"XtalPi \/ Incendia Therapeutics"},{"orgOrder":0,"company":"Eurofins Discovery","sponsor":"Invasight","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eurofins Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eurofins Discovery \/ Invasight","highestDevelopmentStatusID":"3","companyTruncated":"Eurofins Discovery \/ Invasight"},{"orgOrder":0,"company":"Vaccinex","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Vaccinex","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Vaccinex \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Vaccinex \/ Inapplicable"},{"orgOrder":0,"company":"Integral Molecular","sponsor":"Cartexell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Integral Molecular","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Integral Molecular \/ Cartexell","highestDevelopmentStatusID":"3","companyTruncated":"Integral Molecular \/ Cartexell"},{"orgOrder":0,"company":"BioMed X","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioMed X","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioMed X \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"BioMed X \/ Merck Group"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caris Life Sciences \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Inapplicable"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Moderna Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caris Life Sciences \/ Moderna Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Moderna Therapeutics"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Xencor","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0.19,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.19,"dosageForm":"Undisclosed","sponsorNew":"Caris Life Sciences \/ Xencor","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Xencor"},{"orgOrder":0,"company":"Genevant Sciences","sponsor":"Gritstone bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Genevant Sciences","amount2":0.14000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.14000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Genevant Sciences \/ Gritstone bio","highestDevelopmentStatusID":"3","companyTruncated":"Genevant Sciences \/ Gritstone bio"},{"orgOrder":0,"company":"Innate Pharma","sponsor":"Sanofi","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"FRANCE","productType":"Undisclosed","year":"2022","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Innate Pharma","amount2":1.47,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.5,"dosageForm":"Undisclosed","sponsorNew":"Innate Pharma \/ Sanofi","highestDevelopmentStatusID":"3","companyTruncated":"Innate Pharma \/ Sanofi"},{"orgOrder":0,"company":"Y-Biologics","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Y-Biologics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Y-Biologics \/ Pierre Fabre","highestDevelopmentStatusID":"3","companyTruncated":"Y-Biologics \/ Pierre Fabre"},{"orgOrder":0,"company":"BioInvent","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SWEDEN","productType":"Undisclosed","year":"2020","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"BioInvent","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"BioInvent \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"BioInvent \/ Undisclosed"},{"orgOrder":0,"company":"HotSpot Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"HotSpot Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"HotSpot Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"HotSpot Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"Kelonia Therapeutics","sponsor":"ElevateBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Kelonia Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kelonia Therapeutics \/ ElevateBio","highestDevelopmentStatusID":"3","companyTruncated":"Kelonia Therapeutics \/ ElevateBio"},{"orgOrder":0,"company":"Remix Therapeutics","sponsor":"Foresite Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Remix Therapeutics","amount2":0.080000000000000002,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.080000000000000002,"dosageForm":"Undisclosed","sponsorNew":"Remix Therapeutics \/ Foresite Capital","highestDevelopmentStatusID":"3","companyTruncated":"Remix Therapeutics \/ Foresite Capital"},{"orgOrder":0,"company":"Cevec","sponsor":"Rznomics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Cevec","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Cevec \/ Rznomics","highestDevelopmentStatusID":"3","companyTruncated":"Cevec \/ Rznomics"},{"orgOrder":0,"company":"Caris Life Sciences","sponsor":"Incyte Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2023","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Caris Life Sciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Caris Life Sciences \/ Incyte Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Caris Life Sciences \/ Incyte Corporation"},{"orgOrder":0,"company":"Alteogen","sponsor":"Intas Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Enzyme","year":"2021","type":"Collaboration","leadProduct":"ALT-B4","moa":"||Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0.11,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Injection","sponsorNew":"Alteogen \/ Intas Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Intas Pharmaceuticals"},{"orgOrder":0,"company":"Alteogen","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Enzyme","year":"2020","type":"Licensing Agreement","leadProduct":"ALT-B4","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alteogen \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ Undisclosed"},{"orgOrder":0,"company":"Alteogen","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alteogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alteogen \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Alteogen \/ AstraZeneca"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Merck Group","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":1.04,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.04,"dosageForm":"Undisclosed","sponsorNew":"Amphista Therapeutics \/ Merck Group","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Merck Group"},{"orgOrder":0,"company":"AbCellera","sponsor":"Tachyon Technologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Antibody","year":"2021","type":"Collaboration","leadProduct":"TACH204","moa":"LEFTY1","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbCellera","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbCellera \/ Tachyon Technologies","highestDevelopmentStatusID":"3","companyTruncated":"AbCellera \/ Tachyon Technologies"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2022","type":"Inapplicable","leadProduct":"RenNano","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Inapplicable"},{"orgOrder":0,"company":"Biocytogen","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"RenNano","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biocytogen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biocytogen \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Biocytogen \/ Inapplicable"},{"orgOrder":0,"company":"Optieum Biotechnologies","sponsor":"GI CELL","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"JAPAN","productType":"Cell and Gene therapy","year":"2022","type":"Licensing Agreement","leadProduct":"CAR-NK Cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Optieum Biotechnologies","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Optieum Biotechnologies \/ GI CELL","highestDevelopmentStatusID":"3","companyTruncated":"Optieum Biotechnologies \/ GI CELL"},{"orgOrder":0,"company":"The University of Pittsburgh School of Medicine","sponsor":"Coeptis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2023","type":"Licensing Agreement","leadProduct":"SNAP CAR T-cell","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"The University of Pittsburgh School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"The University of Pittsburgh School of Medicine \/ Coeptis Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"The University of Pittsburgh School of Medicine \/ Coeptis Therapeutics"},{"orgOrder":0,"company":"Artiva Biotherapeutics","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"AB-MK-001","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Artiva Biotherapeutics","amount2":1.8700000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.8700000000000001,"dosageForm":"Undisclosed","sponsorNew":"Artiva Biotherapeutics \/ Merck & Co","highestDevelopmentStatusID":"3","companyTruncated":"Artiva Biotherapeutics \/ Merck & Co"},{"orgOrder":0,"company":"Unnatural Products","sponsor":"BridgeBio Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Peptide","year":"2024","type":"Agreement","leadProduct":"Macrocyclic Peptide","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Unnatural Products","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Unnatural Products \/ BridgeBio Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Unnatural Products \/ BridgeBio Pharma"},{"orgOrder":0,"company":"Icahn School of Medicine","sponsor":"Cell BioEngines","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Icahn School of Medicine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Icahn School of Medicine \/ Cell BioEngines","highestDevelopmentStatusID":"3","companyTruncated":"Icahn School of Medicine \/ Cell BioEngines"},{"orgOrder":0,"company":"FutureGen","sponsor":"Gracell Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"FutureGen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"FutureGen \/ Gracell Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"FutureGen \/ Gracell Biotechnologies"},{"orgOrder":0,"company":"Appia Bio","sponsor":"Kite Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Appia Bio","amount2":0.88,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.88,"dosageForm":"Undisclosed","sponsorNew":"Appia Bio \/ Kite Pharma","highestDevelopmentStatusID":"3","companyTruncated":"Appia Bio \/ Kite Pharma"},{"orgOrder":0,"company":"Eigen Therapeutics","sponsor":"Josh Kopelman","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Eigen Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Eigen Therapeutics \/ Josh Kopelman","highestDevelopmentStatusID":"3","companyTruncated":"Eigen Therapeutics \/ Josh Kopelman"},{"orgOrder":0,"company":"GluBio Therapeutics","sponsor":"Qiming Venture Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GluBio Therapeutics","amount2":0.02,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"Undisclosed","sponsorNew":"GluBio Therapeutics \/ Qiming Venture Partners","highestDevelopmentStatusID":"3","companyTruncated":"GluBio Therapeutics \/ Qiming Venture Partners"},{"orgOrder":0,"company":"EvolveImmune Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"EvolveImmune Therapeutics","amount2":1.47,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.47,"dosageForm":"Undisclosed","sponsorNew":"EvolveImmune Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"EvolveImmune Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"Porton Pharma Solutions","sponsor":"Eureka Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Porton Pharma Solutions","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Porton Pharma Solutions \/ Eureka Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Porton Pharma Solutions \/ Eureka Therapeutics"},{"orgOrder":0,"company":"Turbine","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"HUNGARY","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Turbine","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Turbine \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Turbine \/ AstraZeneca"},{"orgOrder":0,"company":"Ajax Therapeutics","sponsor":"EcoR1 Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ajax Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.040000000000000001,"dosageForm":"Undisclosed","sponsorNew":"Ajax Therapeutics \/ EcoR1 Capital","highestDevelopmentStatusID":"3","companyTruncated":"Ajax Therapeutics \/ EcoR1 Capital"},{"orgOrder":0,"company":"Outpace Bio","sponsor":"Century Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Outpace Bio","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Outpace Bio \/ Century Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Outpace Bio \/ Century Therapeutics"},{"orgOrder":0,"company":"Umoja Biopharma","sponsor":"IASO Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2022","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Umoja Biopharma","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Umoja Biopharma \/ IASO Bio","highestDevelopmentStatusID":"3","companyTruncated":"Umoja Biopharma \/ IASO Bio"},{"orgOrder":0,"company":"Engitix Therapeutics","sponsor":"Dompe Farmaceutici","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2022","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Engitix Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"Undisclosed","sponsorNew":"Engitix Therapeutics \/ Dompe Farmaceutici","highestDevelopmentStatusID":"3","companyTruncated":"Engitix Therapeutics \/ Dompe Farmaceutici"},{"orgOrder":0,"company":"Light Horse Therapeutics","sponsor":"Novartis Pharmaceuticals Corporation","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Light Horse Therapeutics","amount2":1.03,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.03,"dosageForm":"Undisclosed","sponsorNew":"Light Horse Therapeutics \/ Novartis Pharmaceuticals Corporation","highestDevelopmentStatusID":"3","companyTruncated":"Light Horse Therapeutics \/ Novartis Pharmaceuticals Corporation"},{"orgOrder":0,"company":"Neomorph","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Neomorph","amount2":1.6399999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.6399999999999999,"dosageForm":"Undisclosed","sponsorNew":"Neomorph \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Neomorph \/ AbbVie Inc"},{"orgOrder":0,"company":"Variational AI","sponsor":"Nimbus Synergies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Variational AI","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Variational AI \/ Nimbus Synergies","highestDevelopmentStatusID":"3","companyTruncated":"Variational AI \/ Nimbus Synergies"},{"orgOrder":0,"company":"SciSparc","sponsor":"N2Off","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"ISRAEL","productType":"Undisclosed","year":"2025","type":"Divestment","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"SciSparc","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SciSparc \/ N2Off","highestDevelopmentStatusID":"3","companyTruncated":"SciSparc \/ N2Off"},{"orgOrder":0,"company":"AbTis","sponsor":"AppClon","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbTis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbTis \/ AppClon","highestDevelopmentStatusID":"3","companyTruncated":"AbTis \/ AppClon"},{"orgOrder":0,"company":"AbTis","sponsor":"Y-Biologics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbTis","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbTis \/ Y-Biologics","highestDevelopmentStatusID":"3","companyTruncated":"AbTis \/ Y-Biologics"},{"orgOrder":0,"company":"DAAN Biotherapeutics","sponsor":"Ligachem Biosciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"DAAN Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DAAN Biotherapeutics \/ Ligachem Biosciences","highestDevelopmentStatusID":"3","companyTruncated":"DAAN Biotherapeutics \/ Ligachem Biosciences"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"Boehringer Ingelheim GmbH","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Expanded Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Biotherapeutics \/ Boehringer Ingelheim GmbH"},{"orgOrder":0,"company":"Oxford Biotherapeutics","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Oxford Biotherapeutics","amount2":1.04,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.04,"dosageForm":"Undisclosed","sponsorNew":"Oxford Biotherapeutics \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"3","companyTruncated":"Oxford Biotherapeutics \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Ginkgo Bioworks","sponsor":"Universal Cells","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Ginkgo Bioworks","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Ginkgo Bioworks \/ Universal Cells","highestDevelopmentStatusID":"3","companyTruncated":"Ginkgo Bioworks \/ Universal Cells"},{"orgOrder":0,"company":"GV20 Therapeutics","sponsor":"Mitsubishi Tanabe Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"GV20 Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"GV20 Therapeutics \/ Mitsubishi Tanabe Pharma","highestDevelopmentStatusID":"3","companyTruncated":"GV20 Therapeutics \/ Mitsubishi Tanabe Pharma"},{"orgOrder":0,"company":"Harbour BioMed","sponsor":"Insilico Medicine","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Harbour BioMed","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Harbour BioMed \/ Insilico Medicine","highestDevelopmentStatusID":"3","companyTruncated":"Harbour BioMed \/ Insilico Medicine"},{"orgOrder":0,"company":"Leveragen","sponsor":"Moonlight Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Leveragen","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Leveragen \/ Moonlight Bio","highestDevelopmentStatusID":"3","companyTruncated":"Leveragen \/ Moonlight Bio"},{"orgOrder":0,"company":"Magnet Biomedicine","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Magnet Biomedicine","amount2":1.29,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1.29,"dosageForm":"Undisclosed","sponsorNew":"Magnet Biomedicine \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Magnet Biomedicine \/ Eli Lilly"},{"orgOrder":0,"company":"Xilio Therapeutics","sponsor":"AbbVie Inc","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Xilio Therapeutics","amount2":2.1499999999999999,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":2.1499999999999999,"dosageForm":"Undisclosed","sponsorNew":"Xilio Therapeutics \/ AbbVie Inc","highestDevelopmentStatusID":"3","companyTruncated":"Xilio Therapeutics \/ AbbVie Inc"},{"orgOrder":0,"company":"AdvanCell","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"AUSTRALIA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AdvanCell","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AdvanCell \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"AdvanCell \/ Eli Lilly"},{"orgOrder":0,"company":"ImmunoPrecise","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"ImmunoPrecise","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"ImmunoPrecise \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"ImmunoPrecise \/ Undisclosed"},{"orgOrder":0,"company":"Alchemab","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2021","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Alchemab","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alchemab \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Alchemab \/ AstraZeneca"},{"orgOrder":0,"company":"Macomics","sponsor":"Institute of Oncology Research","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2024","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Macomics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Macomics \/ Institute of Oncology Research","highestDevelopmentStatusID":"3","companyTruncated":"Macomics \/ Institute of Oncology Research"},{"orgOrder":0,"company":"Nona Biosciences","sponsor":"Atossa Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Nona Biosciences","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Nona Biosciences \/ Atossa Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"Nona Biosciences \/ Atossa Therapeutics"},{"orgOrder":0,"company":"Biovaxys","sponsor":"Sona Nanotech","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CANADA","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Biovaxys","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Biovaxys \/ Sona Nanotech","highestDevelopmentStatusID":"3","companyTruncated":"Biovaxys \/ Sona Nanotech"},{"orgOrder":0,"company":"Peptone","sponsor":"Evotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2025","type":"Partnership","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Peptone","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Peptone \/ Evotec","highestDevelopmentStatusID":"3","companyTruncated":"Peptone \/ Evotec"},{"orgOrder":0,"company":"AbTherx","sponsor":"Spice Biotechnologies","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbTherx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbTherx \/ Spice Biotechnologies","highestDevelopmentStatusID":"3","companyTruncated":"AbTherx \/ Spice Biotechnologies"},{"orgOrder":0,"company":"Stylus Medicine","sponsor":"Eli Lilly","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Stylus Medicine","amount2":0.089999999999999997,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.089999999999999997,"dosageForm":"Undisclosed","sponsorNew":"Stylus Medicine \/ Eli Lilly","highestDevelopmentStatusID":"3","companyTruncated":"Stylus Medicine \/ Eli Lilly"},{"orgOrder":0,"company":"RyboDyn","sponsor":"Moffitt Cancer Center","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"RyboDyn","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"RyboDyn \/ Moffitt Cancer Center","highestDevelopmentStatusID":"3","companyTruncated":"RyboDyn \/ Moffitt Cancer Center"},{"orgOrder":0,"company":"AbTherx","sponsor":"GPCR Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"AbTherx","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"AbTherx \/ GPCR Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"AbTherx \/ GPCR Therapeutics"},{"orgOrder":0,"company":"Taurus Biosciences","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"OmniAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Taurus Biosciences","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Taurus Biosciences \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"Taurus Biosciences \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"xCella","sponsor":"Ligand Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Acquisition","leadProduct":"OmniAb","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"xCella","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"xCella \/ Ligand Pharmaceuticals","highestDevelopmentStatusID":"3","companyTruncated":"xCella \/ Ligand Pharmaceuticals"},{"orgOrder":0,"company":"Horizon Discovery","sponsor":"TrueBinding","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Undisclosed","year":"2020","type":"Licensing Agreement","leadProduct":"Chosource","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Horizon Discovery","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Horizon Discovery \/ TrueBinding","highestDevelopmentStatusID":"3","companyTruncated":"Horizon Discovery \/ TrueBinding"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Advent Life Sciences","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Series A Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Amphista Therapeutics \/ Advent Life Sciences","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Advent Life Sciences"},{"orgOrder":0,"company":"Amphista Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Undisclosed","year":"2020","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Amphista Therapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Amphista Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"3","companyTruncated":"Amphista Therapeutics \/ Inapplicable"},{"orgOrder":0,"company":"DAAN Biotherapeutics","sponsor":"GC Cell","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"SOUTH KOREA","productType":"Undisclosed","year":"2025","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"DAAN Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"DAAN Biotherapeutics \/ GC Cell","highestDevelopmentStatusID":"3","companyTruncated":"DAAN Biotherapeutics \/ GC Cell"},{"orgOrder":0,"company":"VantAI","sponsor":"Halda Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"VantAI","amount2":1,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":1,"dosageForm":"Undisclosed","sponsorNew":"VantAI \/ Halda Therapeutics","highestDevelopmentStatusID":"3","companyTruncated":"VantAI \/ Halda Therapeutics"},{"orgOrder":0,"company":"Synfini","sponsor":"JSL Health Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Other Small Molecule","year":"2025","type":"Financing","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Synfini","amount2":0.01,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"Undisclosed","sponsorNew":"Synfini \/ JSL Health Capital","highestDevelopmentStatusID":"3","companyTruncated":"Synfini \/ JSL Health Capital"},{"orgOrder":0,"company":"Modella AI","sponsor":"AstraZeneca","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Undisclosed","year":"2025","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Modella AI","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Modella AI \/ AstraZeneca","highestDevelopmentStatusID":"3","companyTruncated":"Modella AI \/ AstraZeneca"},{"orgOrder":0,"company":"Dispatch Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell and Gene therapy","year":"2025","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Discovery Platform","graph3":"Dispatch Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Discovery Platform","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Dispatch Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"3","companyTruncated":"Dispatch Biotherapeutics \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Orion Corporation

                            Finland
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Invenra

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Orion, Invenra Sign Deal for Bispecific Antibody Cancer Therapeutics

                            Details : Under the terms of the agreements, Invenra will leverage its B-Body bispecific antibody platform from monoclonal antibody discovery to treat cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 30, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Invenra

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            Fermion Orion Company Banner

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Modella AI

                            Country arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Modella AI

                            Country arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Modella AI Announces Agreement to Accelerate AI-Driven Oncology Clinical Development

                            Details : This agreement aims to harness Modella AI’s advanced models, capable of rich feature extraction from diverse data types, to accelerate clinical development across AstraZeneca’s oncology portfolio.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 02, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : AstraZeneca

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            RyboDyn

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            RyboDyn

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Moffitt Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            RyboDyn Expands Strategic Cancer Immunotherapy Collaboration with Moffitt Cancer Center

                            Details : The collaboration aims to accelerate the development of immunotherapies targeting novel, cancer-specific proteins identified through RyboDyn's sequencing and AI-driven target discovery platform.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 15, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Moffitt Cancer Center

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Stylus Medicine

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Stylus Medicine

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $85.0 million

                            Deal Type : Series A Financing

                            DEALS_DEV arrow-down

                            Stylus Outlines Next-Gen Gene Editing Mission with $85M in Hand

                            Details : Stylus will use this financing to advance its in vivo genetic medicines. The company’s elegant engineering platform combines sequence-specific genome integration with cell-targeted LNP delivery.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 13, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : $85.0 million

                            Deal Type : Series A Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            AbTherx

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            AbTherx

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Spice Biotechnologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            AbTherx and Spice Biotechnologies Announce Multi-Program Antibody Discovery Collaboration

                            Details : The partnership will leverage AbTherx's suite of innovative Atlas Mouse technologies to deliver antibodies against targets selected by Spice Bio.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 12, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Spice Biotechnologies

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Peptone

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Peptone

                            United Kingdom arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Peptone Partners with Evotec to Target IDPs and Scale Small-Molecule Therapies

                            Details : Through the partnership, Peptone will harness Evotec's drug discovery toolbox, encompassing deep domain expertise in oncology and immunology.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 08, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Evotec

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Biovaxys

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Biovaxys

                            Canada arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Sona Nanotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BioVaxys & Sona Nanotech Enter Research Collaboration

                            Details : Through the collaboration, BioVaxys will leverage it's DPX Immune Educating Platform in combination with Sona’s Targeted Hyperthermia Therapy to treat solid tumors.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            May 07, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Sona Nanotech

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            BigHat Biosciences

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            BigHat Biosciences

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            BigHat Biosciences and Lilly Collaborate to Advance AI-Driven Antibody Therapeutics

                            Details : The collaboration combines BigHat's AL/ML-powered Milliner platform with Lilly's expertise in drug discovery to develop high-quality next-generation antibodies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 17, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Eli Lilly

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Nona Biosciences

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            Nona Biosciences

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Atossa Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Nona and Atossa Partner to Develop Next-Gen Breast Cancer Antibodies

                            Details : The collaboration leverages Nona's proprietary H2L2 Harbour Mice platform to identify next-generation therapeutic candidates for breast cancer.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            April 10, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Atossa Therapeutics

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            GV20 Therapeutics

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed

                            GV20 Therapeutics

                            U.S.A arrow
                            SCI Medicinal Chemistry
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Discovery Platform

                            Sponsor : Mitsubishi Tanabe Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            GV20, Mitsubishi Tanabe Partner to Develop Novel Antibody-Drug Conjugates

                            Details : Under this collaboration, MTPC will leverage GV20's antibodies, which are specifically directed against novel tumor antigen targets discovered through STEAD AI platform, to generate ADCs.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            March 26, 2025

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Discovery Platform

                            Sponsor : Mitsubishi Tanabe Pharma

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth